Premium
O2‐13‐02: Diminished levels of cellular protective factors present in neurally enriched exosomes in preclinical Alzheimer's disease
Author(s) -
Mustapic Maja,
Eitan Erez,
Mattson Mark P.,
Goetzl Edward J.,
Kapogiannis Dimitrios
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.07.202
Subject(s) - microvesicles , hsf1 , transcription factor , exosome , enolase , pathogenesis , alzheimer's disease , gene silencing , antibody , biology , immunology , medicine , microbiology and biotechnology , endocrinology , heat shock protein , hsp70 , disease , immunohistochemistry , biochemistry , gene , microrna
we tested the entire metabolite dataset, Random Forest (RF) classifier discriminated pre-conversion samples from non-converters with a classification accuracy of 65.4% and sensitivity/ specificity of 62.0/68.8% respectively. LASSO (least absolute shrinkage and selection operator) gave the best discrimination between samples concurrent to symptom onset versus non-converters (classification accuracy 67.0% and sensitivity/specificity of 70.3/63.6% respectively). Metabolites relevant to classification included phosphatidylcholines, lysophosphatidylcholines, and sphingomyelins. Conclusions: Alterations in serum metabolite concentrations occur early in asymptomatic stages of AD and may be useful as predictive biomarkers of preclinical AD. We were however, unable to replicate the high prediction accuracies reported previously for a panel of metabolites assayed on the same platform. Reference: Mapstone et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med. 2014; 20(4):415-8.